SNMMI introduces infographic explaining nuclear medicine therapy

Reston, Va. (November 20, 2014) — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has released a new infographic showing how certain types of cancer can be treated using nuclear medicine therapy. Targeted Cancer Treatment with Nuclear Medicine Therapy is a visual guide to radioisotope therapy, a personalized treatment where a radioactive drug compound seeks and destroys cancer cells.

The infographic highlights the types of cancer that can be treated with targeted radioisotope therapy (TRT)—including thyroid, liver, prostate, neuroblastoma, non-Hodgkin’s lymphoma, and metastatic neuroendocrine tumors. It breaks down the specific radioisotope treatment for each area and its effectiveness in patients.

Radioisotope therapy is a precision treatment that is highly selective—killing cancer cells and minimizing damage to healthy cells—and can be tailored to the unique molecular properties of the tumor. Virtually all radioisotope therapies are performed as outpatient procedures, and side effect rates are typically less than those of less focused treatments

View the infographic.

For more information about radioisotope therapies, visit: http://bit.ly/11oA3i3.

About the Society of Nuclear Medicine and Molecular Imaging

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to raising public awareness about nuclear medicine and molecular imaging, a vital element of today’s medical practice that adds an additional dimension to diagnosis, changing the way common and devastating diseases are understood and treated and helping provide patients with the best health care possible.

SNMMI’s more than 18,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit www.snmmi.org.

Around the web

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

The all-in-one Omni Legend PET/CT scanner is now being manufactured in a new production facility in Waukesha, Wisconsin.

Trimed Popup
Trimed Popup